NiCord™ is the first product to be developed based on the novel NAM technology. NiCord is being developed in a double cord blood unit configuration. Gamida Cell plans to develop Nicord for treatment of patients with autoimmune diseases.
In 2010 Gamida Cell will begin enrolling patients in a Phase I/II trial studying NiCord. The patients will receive two units of cord blood: one where the population of the stem cells has been artificially increased using the NAM technology and the second, an un-manipulated cord blood unit.
The double cord blood transplant modality tracks the fate and contribution of each cord blood unit to the overall stem cell engraftment.
To view pre-clinical data of NiCord transplanted in a Double CB configuration click here.
To view pre-clinical data of NiCord transplanted in Single vs. Double cord blood transplantation configuration click here. | 
